Becton Dickinson and Co (NYSE:BDX) declared a quarterly dividend on Monday, November 19th, RTT News reports. Investors of record on Monday, December 10th will be paid a dividend of 0.77 per share by the medical instruments supplier on Monday, December 31st. This represents a $3.08 annualized dividend and a yield of 1.26%. The ex-dividend date is Friday, December 7th. This is a boost from Becton Dickinson and’s previous quarterly dividend of $0.75.

Becton Dickinson and has raised its dividend by an average of 9.6% annually over the last three years and has increased its dividend every year for the last 46 years. Becton Dickinson and has a payout ratio of 28.0% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Becton Dickinson and to earn $13.70 per share next year, which means the company should continue to be able to cover its $3.08 annual dividend with an expected future payout ratio of 22.5%.

Shares of BDX stock opened at $244.92 on Thursday. The company has a market cap of $65.70 billion, a P/E ratio of 22.25, a price-to-earnings-growth ratio of 1.69 and a beta of 1.21. The company has a debt-to-equity ratio of 0.90, a quick ratio of 0.69 and a current ratio of 1.03. Becton Dickinson and has a 52-week low of $209.91 and a 52-week high of $265.87.

Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Tuesday, November 6th. The medical instruments supplier reported $2.93 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $2.93. The company had revenue of $4.40 billion for the quarter, compared to analyst estimates of $4.36 billion. Becton Dickinson and had a net margin of 1.47% and a return on equity of 13.88%. Becton Dickinson and’s revenue was up 39.0% compared to the same quarter last year. During the same period last year, the company posted $2.40 earnings per share. Sell-side analysts anticipate that Becton Dickinson and will post 12.1 earnings per share for the current fiscal year.

In other Becton Dickinson and news, Director Timothy M. Ring sold 42,000 shares of Becton Dickinson and stock in a transaction on Wednesday, November 7th. The shares were sold at an average price of $237.07, for a total value of $9,956,940.00. Following the transaction, the director now directly owns 93,688 shares of the company’s stock, valued at $22,210,614.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP James W. Borzi sold 5,887 shares of Becton Dickinson and stock in a transaction on Friday, November 30th. The stock was sold at an average price of $252.37, for a total transaction of $1,485,702.19. Following the completion of the transaction, the executive vice president now directly owns 6,013 shares in the company, valued at $1,517,500.81. The disclosure for this sale can be found here. Insiders sold 81,795 shares of company stock worth $19,571,318 over the last ninety days. Corporate insiders own 1.00% of the company’s stock.

BDX has been the topic of several research reports. Citigroup cut their price objective on shares of Becton Dickinson and from $289.00 to $279.00 and set a “buy” rating on the stock in a report on Tuesday, November 13th. Barclays initiated coverage on shares of Becton Dickinson and in a report on Monday, October 15th. They set an “equal weight” rating and a $278.00 price objective on the stock. Morgan Stanley lifted their price objective on shares of Becton Dickinson and from $250.00 to $280.00 and gave the company an “equal weight” rating in a report on Thursday, October 4th. UBS Group initiated coverage on shares of Becton Dickinson and in a report on Tuesday, November 27th. They set a “neutral” rating and a $260.00 price objective on the stock. Finally, Wells Fargo & Co lifted their price objective on shares of Becton Dickinson and from $275.00 to $290.00 and gave the company an “outperform” rating in a report on Thursday, September 6th. They noted that the move was a valuation call. Six equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Becton Dickinson and currently has an average rating of “Buy” and a consensus price target of $254.20.

TRADEMARK VIOLATION NOTICE: “Becton Dickinson and Co (BDX) Plans Dividend Increase – $0.77 Per Share” was posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.watchlistnews.com/becton-dickinson-and-co-bdx-plans-dividend-increase-0-77-per-share/2664927.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Read More: How to calculate the annual rate of depreciation

Dividend History for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.